177Lu-PSMA-617 is being evaluated for the treatment of metastatic castration-resistant prostate cancer
News
Keytruda made available on the NHS for certain oesophageal cancer patients
Approximately 1,000 people will be eligible for the treatment in England
Novavax joins Oxford mix-and-match COVID-19 vaccine study in adolescents
The Phase II clinical trial will include at least 360 adolescents aged 12-16 years old
Pfizer UK, Entia partner on home blood monitoring device for breast cancer patients
Through Entia’s virtual oncology platform, patients are able to perform their own blood tests
Moderna to collaborate with AbCellera
Partnership aims to develop mRNA-encoded antibody therapeutics
BioCryst’s HAE med Orladeyo wins NICE nod
NICE has recommended the treatment for people who have at least two attacks per month
New research programme aims to combat medulloblastoma
Charity-funded project will aim to develop treatments for the high-grade childhood brain tumour
Research identifies possible link between antibiotic use and breast cancer growth
Researchers discovered that treating mice with broad-spectrum antibiotics increased the rate at which their breast cancer tumours grew
New patient coalition for digital tech in health launches
Coalition unites a range of stakeholders across healthcare
NICE backs Opdivo for head and neck cancer
New evidence collected through the CDF shapes recommendation
Within3 launches new insights management platform
Platform launched in a bid to help life sciences companies address the insights gap
SMC OKs three new meds in latest decisions
Retsevmo, Keytruda and Jyseleca accepted for use by NHS Scotland
First patient receives low-dose psilocybin in rare headache disorder trial
Phase Ib trial is evaluating the potential benefit of low-dose psilocybin as a treatment for SUNHA
England to offer COVID-19 jabs to 12- to 15-year-olds
Children in this age group will be offered one dose of the Pfizer/BioNTech jab from next week
Imfinzi, tremelimumab combo boosts survival outcomes for NSCLC patients
AZ’s combo treatment reduced the risk of disease progression or death by 28% compared to chemotherapy alone
